Growth hormone-releasing factor (1-29)NH2 is inactivated in plasma mainly by dipeptidyl peptidase IV, which cleaves it to GRF(3-29)NH2; analogues substituted to resist that enzyme were far more stable.
emerging — human data exists, and it is thin or contested
every claim resolves to its source
All 3 citations resolve to their original source. · 0 posts naming it, 0 members counted once each.
created page created as 'Mod GRF 1-29' with aliases CJC-1295, CJC-1295 no DAC, CJC-1295 without DAC, Modified GRF (1-29), Tetrasubstituted GRF 1-29 · 2026-09-27 04:00 · somebody
kind set kind set to peptide: palette r1 · 2026-09-27 04:00 · somebody
fact added identity: CAS registry number 863288-34-0. · 2026-09-27 04:00 · somebody
fact added summary: Growth hormone-releasing factor (1-29)NH2 is inactivated in plasma mainly by dipeptidyl peptidase IV, which cleaves it t · 2026-09-27 04:00 · somebody
fact added history: CJC-1295 was built on a tetrasubstituted form of human GRF(1-29), with an albumin-binding lysine derivative added at the · 2026-09-27 04:00 · somebody
fact added history: In eleven healthy men aged 64 to 76, six weeks of nightly subcutaneous GHRH (1-29) self-injections were studied for effe · 2026-09-27 04:00 · somebody
citation added pmid 8583376 cited as preclinical: Dipeptidyl peptidase IV degrades GRF(1-29)NH2; substituted analogues resist it · 2026-09-27 04:00 · somebody
citation added pmid 15817669 cited as preclinical: CJC-1295 described as a tetrasubstituted hGRF(1-29) with an added lysine derivative · 2026-09-27 04:00 · somebody
citation added pmid 9005976 cited as emerging: Nightly GHRH(1-29) injections in healthy elderly men · 2026-09-27 04:00 · somebody
question added Which published studies used the tetrasubstituted GRF(1-29) without the albumin-binding group? · 2026-09-27 04:00 · somebody
Negative findings
failure is information
Nobody has filed a failure yet. Failures are information; this list is waiting for an honest one.